These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 30885238)

  • 1. Expression of zinc finger transcription factors (ZNF143 and ZNF281) in serous borderline ovarian tumors and low-grade ovarian cancers.
    Sadłecki P; Grabiec M; Grzanka D; Jóźwicki J; Antosik P; Walentowicz-Sadłecka M
    J Ovarian Res; 2019 Mar; 12(1):23. PubMed ID: 30885238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of selected epithelial-mesenchymal transition transcription factors in serous borderline ovarian tumors and type I ovarian cancers.
    Sadlecki P; Jóźwicki J; Antosik P; Grabiec M
    Tumour Biol; 2018 Jun; 40(6):1010428318784807. PubMed ID: 29952249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
    Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
    Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers.
    Sadlecki P; Walentowicz P; Bodnar M; Marszalek A; Grabiec M; Walentowicz-Sadlecka M
    Tumour Biol; 2017 May; 39(5):1010428317706230. PubMed ID: 28488545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and prognostic significance of epithelial-mesenchymal transition-related markers and phenotype in serous ovarian cancer.
    Song IH; Kim KR; Lim S; Kim SH; Sung CO
    Pathol Res Pract; 2018 Oct; 214(10):1564-1571. PubMed ID: 30082157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ZNF281/ZBP-99: a new player in epithelial-mesenchymal transition, stemness, and cancer.
    Hahn S; Hermeking H
    J Mol Med (Berl); 2014 Jun; 92(6):571-81. PubMed ID: 24838609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ZNF143 enhances metastasis of gastric cancer by promoting the process of EMT through PI3K/AKT signaling pathway.
    Wei S; Wang L; Zhang L; Li B; Li Z; Zhang Q; Wang J; Chen L; Sun G; Li Q; Xu H; Zhang D; Xu Z
    Tumour Biol; 2016 Sep; 37(9):12813-12821. PubMed ID: 27449034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 10. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
    Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
    Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of p53 induces invasion of serous borderline ovarian tumor cells by accentuating PI3K/Akt-mediated suppression of E-cadherin.
    Cheng JC; Auersperg N; Leung PC
    Oncogene; 2011 Mar; 30(9):1020-31. PubMed ID: 20972462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteration of epithelial-mesenchymal transition markers in human normal ovaries and neoplastic ovarian cancers.
    Yi BR; Kim TH; Kim YS; Choi KC
    Int J Oncol; 2015 Jan; 46(1):272-80. PubMed ID: 25310727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
    Yamaguchi N; Mimoto R; Yanaihara N; Imawari Y; Hirooka S; Okamoto A; Yoshida K
    Tumour Biol; 2015 Aug; 36(8):5913-23. PubMed ID: 25712377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
    Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
    J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discrepant clinicopathologic characteristics and HE4 performance in type I and type II epithelial ovarian cancer.
    Jiang J; Bo D; Chang X; Cheng H; Ye X; Cui H
    Int J Clin Exp Med; 2015; 8(11):21303-10. PubMed ID: 26885070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
    Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
    Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: a retrospective study.
    Brunette LL; Mhawech-Fauceglia PY; Ji L; Skeate JG; Brand HE; Lawrenson K; Walia S; Chiriva-Internati M; Groshen S; Roman LD; Kast WM; Da Silva DM
    BMC Cancer; 2018 Oct; 18(1):970. PubMed ID: 30309325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing for
    Sadlecki P; Grzanka D; Grabiec M
    Dis Markers; 2018; 2018():1497879. PubMed ID: 29682098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRAP1 downregulation in human ovarian cancer enhances invasion and epithelial-mesenchymal transition.
    Amoroso MR; Matassa DS; Agliarulo I; Avolio R; Lu H; Sisinni L; Lettini G; Gabra H; Landriscina M; Esposito F
    Cell Death Dis; 2016 Dec; 7(12):e2522. PubMed ID: 27977010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Principles of Treatment for Borderline, Micropapillary Serous, and Low-Grade Ovarian Cancer.
    Hacker KE; Uppal S; Johnston C
    J Natl Compr Canc Netw; 2016 Sep; 14(9):1175-82. PubMed ID: 27587627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.